Clinical Trial Results:
An open-label, phase IIb study to determine acute (after the first dose administration) and chronic (after 28 days of treatment) effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor BI 10773 (25 mg once daily) on pre and postprandial glucose homeostasis in patients with IGT and type 2 diabetes mellitus
Summary
|
|
EudraCT number |
2010-018708-99 |
Trial protocol |
IT DE AT |
Global completion date |
08 Jul 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 Mar 2016
|
First version publication date |
10 Mar 2016
|
Other versions |
|
Summary report(s) |
Trial Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.